Neuroendocrine tumors (NETs) are rare neoplasms characterized by a low proliferative index and, in some cases, a favorable prognosis. These tumors often overproduce and release biologically active substances that are responsible for severe syndromes. Tumor marker measurement provides the clinician with useful information for the management of NET patients. The substances released by overproducing tumors are currently used as biomarkers, but there is a need for sensitive markers also for the “biochemically silent” NETs. The most effective and reliable blood marker available today is chromogranin A (CgA). Because of its high sensitivity and specificity, this glycoprotein can be used for the diagnosis, prognosis and follow-up of NETs. Furthermore, CgA measurement can be used for monitoring those tumors not overproducing or releasing any hormones or biological amines. This paper is a synthetic review on the value of CgA in NET management and reports our experiences with CgA measurement in NET patients.
NearyP.C., RedmondP.H., HoughtonT., WatsonG.R.K., Bouchier-HayesD.Carcinoid disease. Review of the literature.Dis Colon Rectum1997; 40: 349–62.
2.
CapellaC., HeitzP.U., HöflerH., SolciaE., KlöppelG.Revised classification of neuroendocrine tumours of the lung, pancreas and gut.Virchows Archiv1995; 425: 547–60.
3.
HauserH., WolfG., UranüsS., KlimpfingerM.Neuroendocrine tumours in various organ systems in a ten-year period.Eur J Surgical Oncol1995; 21: 297–300.
4.
FeldmanJ.M.Carcinoid tumors and syndrome.Semin Oncol1987; 14: 237–46.
5.
WolfeM.M., JensenR.T.Zollinger-Ellison syndrome. Current concepts in diagnosis and management.N Engl J Med1987; 317: 1200–09.
6.
VinikA.I., GoninJ., EnglandB.J., JacksonT., McLeodM.K.Plasma substance-P in neuroendocrine tumors and idiopathic flushing: the value of pentagastrin stimulation tests and the effects of somatostatin analog.J Clin Endocrinol Metab1990; 70: 1702–09.
7.
DanforthD.N.Jr., GordenP., BrennanM.F.Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery.Surgery1984; 96: 1027–37.
8.
O'ConnorD.T., DeftosL.J.Secretion of chromogranin A by peptide-producing endocrine neoplasms.N Engl J Med1986; 314: 1145–51.
9.
ErikssonB., ArnbergH., ÖbergK.. Chromogranins - New sensitive markers for neuroendocrine tumors.Acta Oncol1989; 28: 325–9.
CohnD.V., EltingJ.J., FrickM., EldeR.Selective localization of the parathyroid secretory protein I/adrenal medulla chromogranin A protein family in a wide variety of endocrine cells of the rat.Endocrinol1984; 114: 1963–74.
Sanchez-MargaletV., LucasM., GobernaR.Pancreastatin: Further evidence for its consideration as a regulatory peptide.J Molec Endocrinol1996; 16: 1–8.
18.
KirchmairR., LeitnerB., Fischer-ColbrieR., MarksteinerJ., Hogue-AngelettiR., WinklerH.Large variations in the proteolytic formation of a chromogranin A-derived peptide (GE-25) in neuroendocrine tissues.Biochem J1995; 310: 331–6.
19.
SimonJ-P, BaderM-F, AunisD.Secretion from chromaffin cells is controlled by chromogranin A-derived peptides.Proc Natl Acad Sci USA1988; 85: 1712–6.
20.
BenedumU.M., BaeuerleP.A., KoneckiD.S.. The primary structure of bovine chromogranin A: a representative of a class of acidic secretory proteins common to a variety of peptidergic cells.EMBO J1986; 5: 1495–502.
21.
WinklerH., AppsD.K., Fischer-ColbrieR.The molecular function of adrenal chromaffin granules: established facts and unresolved topics.Neuro science1986; 18: 261–90.
22.
FalkensammerG., Fischer-ColbrieR., WinklerH.Biogenesis of chromaffin granules: incorporation of sulfate into chromogranin B and into a proteoglycan.J Neurochem1985; 45: 1475–80.
23.
ModlinE.M., TangL.H.Approaches to the diagnosis of gut neuroendocrine tumours: the last word (today).Gastroenterol1997; 112: 583–90.
24.
SakamotoT., MiyataM., IzukuraM.. Role of endogenous somatostatin in postprandial hypersecretion of neurotensin in patients after gastrectomy.Ann Surg1997; 225: 377–81.
25.
ErikssonB., ÖbergK.Peptide hormones as tumor markers in neuroendocrine gastrointestinal tumors.Acta Oncol1991; 30: 477–83.
26.
SchürmannG., RaethU., WiedenmannB.Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract.World J Surg1992; 16: 697–702.
27.
HallerD.G.Endocrine tumors of the gastrointestinal tract.Curr Opinion Oncol1994; 6: 72–6.
NobelsF.R.E., KwekkeboomD.J., CoopmansW.. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the α-subunit of glycoprotein hormones.J Clin Endocrinol Metab1997; 82: 2622–8.
30.
JansonE.T., HolmbergL., StridsbergM.. Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center.Ann Oncol1997; 8: 685–90.
31.
NanesM.S., O'ConnorD.T., MarxS.J.Plasma chromogranin A in primary hyperparathyroidism.J Clin Endocrinol Metab1989; 320: 444–7.
32.
StabileB.E., HowardsT.J., PassaroE., O'ConnorD.T.Source of plasma chromogranin A elevation in gastrinoma patients.Arch Surg1990; 125: 451–53.
33.
AddisB.J.Neuroendocrine differentiation in lung carcinoma.Thorax1995; 50: 113–15.
34.
SobolR.E., O'ConnorD.T., AddisonJ., SuchockiK., RoystonI., DeftosL.J.Elevated serum chromogranin A concentrations in small cell lung carcinoma.Ann Intern Med1986; 105: 698–700.
35.
DeftosL.J.Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker.Endocr Rev1991; 12: 181–7.
36.
JohnsonP.W.M., JoelS.P., LoveS.. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer.Br J Cancer1993; 67: 760–6.
37.
SmithA.F., WinklerH.Purification and properties of an acidic protein from chromaffin granules of bovine adrenal medulla.Biochem J1967; 103: 483–92.
38.
O'ConnorD.T., FrigonR.P., SokoloffR.L.Human chromogranin A: purification and characterization from catecholamine storage vesicles of human pheochromocytoma.Hypertension1984; 6: 2–12.
39.
O'ConnorD.T., FrigonR.P.Chromogranin A, the major catecholamine storage vesicle soluble protein: multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay.J Biol Chem1984; 259: 3237–47.
O'ConnorD.T., BernsteinK.N.Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma.New Engl J Med1984; 311: 764–70.
42.
HsiaoR.J., ParmerR.J., TakiyyuddinM.A., O'ConnorD.T.Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma.Medicine1991; 70: 33–45.
43.
StridsbergM., HusebyeE.S.Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma.Eur J Endocrinol1997; 136: 67–73.
44.
HsiaoR.J., NeumannH.P.H., ParmerR.J., BarbosaJ.A., O'ConnorD.T.Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumour mass, and post-resection kinetics indicating two-compartment distribution.Am J Med1990; 88: 607–13.
45.
HsiaoR.J., SeegerR.C., YuA.L., O'ConnorD.T.Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival.J Clin Invest1990; 85: 1555–9.
46.
WassbergE., StridsbergM., ChristoffersonR.Plasma levels of chromogranin A are directly proportional to tumour burden in neuroblastoma.J Endocrinol1996; 151: 225–30.
47.
SchürmannG., BetzlerM., BuhrH.J.Chromogranin A, neuron-specific enolase and synaptophysin as neuroendocrine cell markers in the diagnosis of tumours of the gastro-entero-pancreatic system.Eur J Surg Oncol1990; 16: 298–303.
